Rigel Secures Hepatitis C Virus License Agreement From Chiron Corporation
Advertisement
Rigel Pharmaceuticals, Inc. announced that it has entered into a nonexclusive licensing agreement with Chiron Corporation granting Rigel a license to discover, develop and commercialize small molecule therapeutics against certain hepatitis C virus (HCV) drug targets. The financial terms and other details of the license were not disclosed.
"Today's agreement provides Rigel with the flexibility to pursue our innovative HCV research program and develop potential breakthrough treatments for HCV," stated James M. Gower, chairman and chief executive officer. "We believe that Rigel's lead drug candidate, R803, has the potential to become an anchor of therapeutic approaches to treating this intractable virus."
The prevalence of HCV infection in the United States has been estimated at nearly 4 million, with approximately 170 million infected worldwide.(1) Rigel's lead HCV small-molecule drug candidate, R803, rapidly and selectively targets HCV and potentially stops replication of the virus by interfering with the viral polymerase, a protein needed for viral replication. Rigel believes that R803 will be one of the first direct antivirals to enter development and is substantially different from interferon alpha, the main current therapy, which primarily works indirectly to boost the immune system.
Most read news
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Study fails to link phthalates and increased breast cancer risk - Epidemiologist says more research is needed looking at younger women

Cresset Announces Appointment of David Bardsley as Sales Director
Category:Taxonomic_lists_(genera,_taxonomic)
Immatics wins 2012 TiE50 Award

Purple tomatoes thanks to red beet pigment - Genetic Engineering methods of producing substances in specially developed plant production systems will play an important role in the future, especially in drug manufacturing
Cresset BioMolecular Discovery and Bayer CropScience announce a collaboration on molecular field technology
Novel process for DNA labeling
